Human mass balance, metabolism, and cytochrome P450 phenotyping of lusutrombopag-Reference-Cited by-同舟云学术

Human mass balance, metabolism, and cytochrome P450 phenotyping of lusutrombopag

Published:2020-11-16 Issue:3 Volume:51 Page:287-296
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Kawachi Tomoyuki¹^ORCID,Ninomiya Mizuki¹,Katsube Takayuki²,Wajima Toshihiro²,Kanazu Takushi¹

Affiliation:

1. Drug Metabolism and Pharmacokinetics, Shionogi & Co., Ltd, Osaka, Japan

2. Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd, Osaka, Japan

Funder

Shionogi & Co., Ltd.

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2020.1845416

Reference12 articles.

1. European Medicines Agency. 2012. Guideline on the investigation of drug interactions [online]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf [Accessed 22 Oct 2020].

2. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases

3. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation

4. CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis

5. Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of the methoxy group in approved drugs;European Journal of Medicinal Chemistry;2024-07

2. Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide;Chemico-Biological Interactions;2023-09

3. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023